Harmony Biosciences (HRMY) to Announce Quarterly Earnings on Tuesday

Harmony Biosciences (NASDAQ:HRMY) is expected to post its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of $0.97 per share and revenue of $249.0060 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:30 AM ET.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.21). Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The firm had revenue of $215.39 million during the quarter, compared to analyst estimates of $220.84 million. During the same period last year, the company earned $0.78 EPS. The company’s revenue was up 16.6% on a year-over-year basis. On average, analysts expect Harmony Biosciences to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Harmony Biosciences Price Performance

Shares of HRMY stock opened at $36.01 on Tuesday. The stock has a 50 day moving average of $34.07 and a two-hundred day moving average of $32.59. The company has a current ratio of 3.58, a quick ratio of 3.56 and a debt-to-equity ratio of 0.15. Harmony Biosciences has a 12 month low of $25.52 and a 12 month high of $40.87. The company has a market capitalization of $2.08 billion, a P/E ratio of 14.52, a P/E/G ratio of 0.33 and a beta of 0.94.

Institutional Trading of Harmony Biosciences

A number of large investors have recently bought and sold shares of the stock. National Bank of Canada FI bought a new position in shares of Harmony Biosciences during the third quarter valued at $40,000. Kestra Advisory Services LLC bought a new stake in shares of Harmony Biosciences in the 4th quarter worth about $47,000. PNC Financial Services Group Inc. grew its holdings in shares of Harmony Biosciences by 30.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,663 shares of the company’s stock worth $100,000 after purchasing an additional 619 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Harmony Biosciences by 338.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,511 shares of the company’s stock worth $111,000 after purchasing an additional 2,711 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new stake in shares of Harmony Biosciences during the 2nd quarter worth about $120,000. 86.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

HRMY has been the topic of a number of research reports. Truist Financial boosted their price objective on Harmony Biosciences from $25.00 to $29.00 and gave the company a “hold” rating in a research report on Friday, May 8th. Zacks Research raised Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Harmony Biosciences from $30.00 to $36.00 and gave the stock a “hold” rating in a research note on Tuesday, June 30th. HC Wainwright reissued a “buy” rating and issued a $55.00 price target on shares of Harmony Biosciences in a report on Thursday, July 16th. Finally, Weiss Ratings upgraded shares of Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, June 23rd. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.50.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.